Sernova Biotherapeutics Inc SVA.TO
TSX
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 26.88% | -42.99% | -6.32% | 46.60% | -11.57% |
| Total Depreciation and Amortization | 0.00% | 0.00% | -92.86% | -66.74% | 302.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -16.52% | 78.22% | -36.70% | 111.20% | -21.70% |
| Change in Net Operating Assets | 8,777.27% | -100.92% | -32.53% | -28.28% | 296.03% |
| Cash from Operations | 55.97% | -113.30% | -512.33% | 91.83% | 44.13% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 314.29% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 314.29% | -- |
| Total Debt Issued | -100.00% | -- | -- | -47.90% | -96.28% |
| Total Debt Repaid | 100.00% | -- | -- | 66.50% | 53.12% |
| Issuance of Common Stock | -100.00% | 311.71% | 380.14% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -200.00% | 520.88% | -- | -- |
| Cash from Financing | -100.00% | 99.95% | 308.94% | 114.41% | -96.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -303.79% | 55.04% | 71.69% | 109.38% | -350.62% |